When oxygen is abundant, quiescent cells efficiently extract energy from glucose primarily by oxidative phosphorylation, whereas under the same conditions tumour cells consume glucose more avidly, converting it to lactate. This long-observed phenomenon is known as aerobic glycolysis 1 , and is important for cell growth 2, 3 . Because aerobic glycolysis is only useful to growing cells, it is tightly regulated in a proliferation-linked manner 4 . In mammals, this is partly achieved through control of pyruvate kinase isoform expression. The embryonic pyruvate kinase isoform, PKM2, is almost universally re-expressed in cancer 2 , and promotes aerobic glycolysis, whereas the adult isoform, PKM1, promotes oxidative phosphorylation 2 . These two isoforms result from mutually exclusive alternative splicing of the PKM pre-mRNA, reflecting inclusion of either exon 9 (PKM1) or exon 10 (PKM2). Here we show that three heterogeneous nuclear ribonucleoprotein (hnRNP) proteins, polypyrimidine tract binding protein (PTB, also known as hnRNPI), hnRNPA1 and hnRNPA2, bind repressively to sequences flanking exon 9, resulting in exon 10 inclusion. We also demonstrate that the oncogenic transcription factor c-Myc upregulates transcription of PTB, hnRNPA1 and hnRNPA2, ensuring a high PKM2/PKM1 ratio. Establishing a relevance to cancer, we show that human gliomas overexpress c-Myc, PTB, hnRNPA1 and hnRNPA2 in a manner that correlates with PKM2 expression. Our results thus define a pathway that regulates an alternative splicing event required for tumour cell proliferation.
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Alternative splicing of PKM has an important role in determining the metabolic phenotype of mammalian cells. The single exon difference imparts the enzymes produced with important functional distinctions. For example, PKM2, but not PKM1, is regulated by the binding of tyrosine phosphorylated peptides, which results in release of the allosteric activator fructose-1-6-bisphosphate and inhibition of pyruvate kinase activity 5 , a property that might allow growthfactor-initiated signalling cascades to channel glycolytic intermediates into biosynthetic processes. The importance of tumour reversion to PKM2 was underscored by experiments in which replacement of PKM2 with PKM1 in tumour cells resulted in markedly reduced growth 2 . Consistent with a critical role in proliferation, re-expression of PKM2 in tumours is robust 2 , although little is known about the regulation of this process.
We set out to identify RNA binding proteins that might regulate PKM alternative splicing. To this end, we prepared an [a-32 P]UTPlabelled 250-nucleotide RNA spanning the exon 9 (E9) 59 splice site (EI9), previously identified as inhibitory to E9 inclusion 6 , as well as a labelled RNA from a corresponding region of E10 (EI10) (Fig. 1b) , and performed ultraviolet crosslinking assays with HeLa nuclear extracts 7 . After separation by SDS-polyacrylamide gel electrophoresis (PAGE), multiple proteins from 35-40 kDa appeared using the EI9 substrate, whereas little binding was observed using the EI10 substrate (Fig. 1b) . Strong binding was mapped to a 19-nucleotide region we named EI9(50-68) that spans the E9 59 splice site ( Supplementary  Fig. 1 ). To identify the bound proteins, we performed RNA affinity chromatography using a 59 biotin-labelled RNA corresponding to EI9(50-68). After SDS-PAGE and Coomassie staining, the pattern of specifically bound proteins closely matched that observed after ultraviolet crosslinking (Fig. 1c) . The four indicated proteins between 35-40 kDa were excised and identified by mass spectrometry as isoforms of hnRNPA1 and hnRNPA2, RNA binding proteins with well established roles as sequence-specific repressors of splicing (for example, see refs 7, 8) . This result was confirmed by immunoblotting with antibodies against hnRNPA1 ( Supplementary Fig. 2 ).
The sequence immediately downstream of the E9 59 splice site contains a UAGGGC sequence that is highly related to the consensus hnRNPA1 high affinity binding site identified by SELEX, UAGGG(A/ U) 9 ( Fig. 1d ). Consistent with previous mutational studies of an identical A1 binding site 8 , mutation of the G3 nucleotide of this motif to C led to a large decrease in hnRNPA1 and hnRNPA2 binding ( Fig. 1d and Supplementary Fig. 3 ). The G3C mutation resulted in increased splicing in vitro when introduced into a splicing substrate containing E9 ( Supplementary Fig. 4) , and led to increased E9 inclusion in a minigene construct in vivo ( Supplementary Fig. 5 ). These data confirm the presence of an inhibitory hnRNPA1/hnRNPA2 binding site immediately downstream of the E9 59 splice site.
To explore the possibility that other splicing regulators bind upstream of E9 or E10, we constructed crosslinking substrates (48 nucleotides) that span the region upstream of each exon. Using these RNAs for ultraviolet crosslinking we showed strong binding of a 55-kDa protein to the I8 RNA probe, but not to the I9 probe (Fig. 1e) . Inspection of the polypyrimidine tract upstream of E9 revealed two potential PTB (polypyrimidine tract binding protein, or hnRNPI) binding sequences (UCUUC) 10 within 35 nucleotides of the intron/ exon boundary, whereas no such sequence exists in the E10 polypyrimidine tract. PTB frequently functions as a splicing repressor 10 , often by binding repressively to the polypyrimidine tract 11 . Immunoprecipitation confirmed that the 55-kDa crosslink observed using I8 RNA is PTB (Fig. 1e) , and we observed strong binding of PTB to a biotinylated version of I8 ( Supplementary Fig. 6 ). In addition, mutation of the two putative PTB binding sites from UCUUC to UGUUC significantly diminished binding ( Fig. 1f and Supplementary Fig. 7 ). Our data indicate that the splicing repressor PTB binds specifically to the polypyrimidine tract of E9.
Because the locations of hnRNPA1/hnRNPA2 and PTB binding sites flanking E9 overlap elements critical to exon inclusion (the polypyrimidine tract for PTB 11 , the site of U1 snRNA-pre-mRNA base-pairing for hnRNPA1/hnRNPA2 12 ), we speculated that these proteins are inhibitors of E9 inclusion. To examine this possibility, we used short interfering RNA (siRNA) to deplete hnRNPA1, hnRNPA2 and/or PTB from HeLa cells. We assayed the PKM messenger RNA isoform ratio using RT-PCR followed by exonspecific restriction digestion (Fig. 2a) . Knockdown of hnRNPA1 or hnRNPA2 in HeLa cells resulted in little change in splicing pattern ( Supplementary Fig. 8 ). Because we have previously observed functional redundancy of hnRNPA1 and hnRNPA2 (ref. 7) , we next simultaneously depleted both proteins (Fig. 2b) . This resulted in an increase in PKM1 mRNA, from 2% to 29%, and a concomitant decrease in PKM2 mRNA ( Fig. 2c and Supplementary Fig. 8 ). PTB knockdown also increased the PKM1 isoform, to 16% ( Fig. 2c and Supplementary Fig. 8 ), consistent with earlier observations 13 . Next, we simultaneously depleted all three factors, which further increased PKM1 levels to about 48% (Fig. 2c) . Similar results were obtained using 293 cells, with the triple knockdown resulting in an increase from 5% to 67% PKM1 (Fig. 2d) . Increases in PKM1 mRNA upon knockdown of hnRNPA1, hnRNPA2 and PTB were observed in all cell lines tested, including the breast cancer cell line MCF-7 and the glioblastoma cell line U87 ( Supplementary Fig. 9 ). Knockdown of two other cancer-associated splicing factors in HeLa cells, the SR proteins ASF/SF2 and SRp20, while also resulting in slowed growth, failed to affect PKM1/PKM2 ratios significantly (Supplementary Figs 8 and 10), indicating that the effects seen in PTB/hnRNPA1/ hnRNPA2-depleted cells on PKM splicing are specific and not the result of pleiotropic effects due to changes in cell growth. Together, our results indicate that expression of PTB, hnRNPA1 and hnRNPA2 is the critical determinant of PKM isoform in transformed cells.
We next wished to determine whether expression levels of PTB, hnRNPA1 and hnRNPA2 and alternative splicing of PKM are correlated. We first examined whether changes in PTB, hnRNPA1 and hnRNPA2 levels correlate with changes in PKM splicing during switching from growth to quiescence. To this end, we used the mouse myoblast cell line C2C12, which, when grown to confluence and then switched to low-serum medium, undergoes myogenic differentiation, a process that includes PKM2 to PKM1 switching 14 . We differentiated C2C12 cells for 6 days, and used RT-PCR followed by restriction digestion to assess the PKM1/PKM2 ratio each day. We observed a large increase in Pkm1 and a corresponding decrease in Pkm2 mRNA during differentiation (Fig. 3a) . We then prepared lysates of C2C12 cells at time points throughout differentiation and examined protein levels by immunoblotting (Fig. 3b ). PTB expression dropped over 70% by day 3 of differentiation, after which it remained stable, consistent with previous studies 15 . We also observed an approximately 50% decrease in hnRNPA1 levels by day 3 of differentiation, although no significant changes were observed in the level of hnRNPA2. This result is consistent with a role for PTB and hnRNPA1 in maintaining high PKM2 levels in proliferating C2C12 cells.
Because of the importance of the PKM2 isoform to the growth of cancer cells, we next examined human glioma tumour samples for a correlation between PTB, hnRNPA1 and hnRNPA2 expression and PKM splicing. We first assayed PKM1 and PKM2 mRNA levels as described earlier. Normal brain tissue ranged from 4% to 13% PKM2, pilocytic astrocytoma samples expressed approximately 66-77% PKM2, low-grade astrocytomas ranged from 7% to 73%, and glioblastoma multiforme samples expressed 72-86% PKM2 (Fig. 3c) . To explore a potential correlation between elevated PKM2 mRNA levels and expression of the regulatory proteins we identified, we performed immunoblots for PTB, hnRNPA1 and hnRNPA2. Notably, all high-PKM2 tumours expressed elevated levels of PTB, hnRNPA1 and hnRNPA2, with the most striking overexpression in glioblastoma multiforme samples (Fig. 3d) . Consistent with their uniformly high PKM2 expression, all four pilocytic astrocytoma samples also showed overexpression of PTB, hnRNPA1 and hnRNPA2. In lowgrade astrocytomas the two high-PKM2 tumours showed elevated expression of the three proteins, whereas the two low-PKM2 tumours showed expression levels similar to normal brain. Immunoblotting for four other splicing factors (ASF/SF2, Tra2b, TLS (also called FUS) and hnRNPK) revealed no correlation with PKM2 expression ( Supplementary Fig. 11 ), indicating that the correlation between an elevated PKM2/PKM1 mRNA ratio and overexpression of PTB, hnRNPA1 and hnRNPA2 is specific and not reflective of a general property of splicing factors.
The tight coupling of PKM2 expression to proliferation suggests that expression of the PKM splicing regulatory proteins we identified might be under the control of a proliferation-associated regulatory mechanism. A strong candidate to control this is the oncogenic transcription factor c-Myc, which, like PTB, hnRNPA1 and hnRNPA2, is upregulated in glioblastoma multiforme 16 , and has been shown to bind the PTB, hnRNPA1 and hnRNPA2 promoters 17, 18 and upregulate the expression of all three 19, 20 . Consistent with a role for c-Myc in PTB, hnRNPA1 and hnRNPA2 regulation, we observed a near perfect correlation between the levels of c-Myc and those of PTB, hnRNPA1 and hnRNPA2 in gliomas and differentiating C2C12 cells (Fig. 3b, d) . Furthermore, the transcription factor N-Myc, which is closely related to c-Myc 21 , was upregulated in pilocytic astrocytomas and to a lesser extent in glioblastoma multiforme samples ( Supplementary Fig. 11 ), indicating that this protein may in some cases contribute to PTB, hnRNPA1 and hnRNPA2 upregulation.
We next examined directly the involvement of c-Myc in expression of PTB, hnRNPA1 and hnRNPA2 and splicing regulation of PKM. We first asked whether decreasing c-Myc levels can affect PTB, hnRNPA1 and hnRNPA2 levels and the Pkm1/Pkm2 mRNA ratio. To this end, we stably transfected NIH-3T3 cells with vectors bearing a puromycinresistance marker that express either a c-Myc-targeting short hairpin RNA (shRNA) or a control shRNA. Immunoblotting showed a reduction in c-Myc levels in cells stably transfected with c-myc shRNA compared to control cells (Fig. 4a) . Protein levels of PTB, hnRNPA1 and hnRNPA2 were also significantly reduced after depletion of c-Myc, in contrast with two other RNA processing factors not implicated in PKM splicing regulation; that is, ASF/SF2 and CPSF73 (Fig. 4a) . Ptb, Hnrnpa1 and Hnrnpa2 mRNA levels were also significantly reduced in the knockdown cells (Fig. 4b) , supporting the idea that c-Myc regulates transcription of these genes. Importantly, the cells expressing the c-myc shRNA showed a pronounced increase in the Pkm1/Pkm2 ratio, expressing 33% Pkm1 mRNA compared to 7% in the control (Fig. 4c) . A separate line stably expressing a second c-myc shRNA revealed a similarly elevated Pkm1/Pkm2 ratio, as well as reduced levels of PTB, hnRNPA1 and hnRNPA2, showing that the observed effects were not due to off-target effects of the c-myc shRNA ( Supplementary Fig. 12 ). Additionally, we transiently co-transfected HeLa cells with an hnRNPA1 promoter-luciferase construct with a c-Myc expression vector 22 , which resulted in a dose-and c-Myc-binding-site-dependent increase in promoter activity (Supplementary Fig. 13) .
The above results demonstrate a direct role for c-Myc in maintaining high PTB, hnRNPA1 and hnRNPA2 levels in NIH-3T3 cells. In contrast, c-Myc knockdown in HeLa cells revealed only a small decrease in PTB, hnRNPA1 and hnRNPA2 levels, and no change in the PKM1/PKM2 ratio ( Supplementary Fig. 14) , indicating that factors other than c-Myc might promote PTB, hnRNPA1 and hnRNPA2 expression in these cells. One possibility is the transcription factor E2F1, which, like c-Myc, binds upstream of all three genes 18 . However, knockdown of E2F1, or of Rb, a negative regulator of E2F family transcription factors 23 , resulted in little change in PTB, hnRNPA1 and hnRNPA2 levels (C.J.D., M.C. and J.L.M., unpublished data). However, because the E2F and Rb families exhibit redundancy, this result does not rule out involvement of the E2F/Rb pathway in regulation of PTB, hnRNPA1 and hnRNPA2. Indeed, because of their importance to proliferating cells, it is likely that PTB, hnRNPA1 and hnRNPA2 can be upregulated by proliferation-associated factors in addition to c-Myc.
The fact that PTB, hnRNPA1 and hnRNPA2 depletion results in switching to the PKM1 isoform suggests that RNA binding proteins can control the outcome of a mutually exclusive splicing event by simultaneously acting as repressors of one exon (E9) and activators of the other (E10) (Fig. 4d) . Although it is easy to envision how these proteins exclude E9, how might PTB, hnRNPA1 and hnRNPA2 promote E10 inclusion? A variety of RNA binding proteins, including hnRNPA1 and hnRNPA2, have been shown to stimulate splicing of an adjacent exon through intronic binding sites 24 . One proposed mechanism for this is intron definition, in which intron-binding proteins induce intronic structures conducive to inclusion of the neighbouring exon 24 . We propose that, like many alternatively spliced exons, PKM E10 is poorly recognized by the splicing machinery in the absence of adjacent intron definition, and such a structure is promoted by PTB, hnRNPA1 and hnRNPA2 binding (Fig. 4d) .
We have demonstrated a critical functional consequence for observations connecting PTB, hnRNPA1 and hnRNPA2 upregulation with cell proliferation 25, 26 , transformation 27,28 and a wide variety of cancers (for example, see refs 26, 27, 29, 30) . Given the critical role of these proteins in promoting PKM2 production in tumours, overexpression of some combination of them is, like PKM2 expression, likely to be a general phenomenon in cancer. The fact that the proteins show some redundancy in promoting PKM2 splicing may ensure robust re-expression of PKM2 in tumours.
METHODS SUMMARY
Ultraviolet crosslinking substrates were cloned into the pcDNA3 vector (Invitrogen) and ultraviolet crosslinking was performed as previously described 7 . Mutations were introduced in EI9 by PCR-based site-directed mutagenesis. Biotinylated RNAs for affinity purification were purchased from Dharmacon, and RNA affinity chromatography was carried out as described 7 . Immunoprecipitations were carried out using protein A-agarose beads (Roche). RNA interference was performed as described 7 . We transfected 50 pmol of hnRNPA1 siRNA and 25 pmol of other siRNA duplex in a 24-well plate. After 72 h, we collected cells for RNA isolation and immunoblotting. C2C12 cells were grown in DMEM (Invitrogen) supplemented with 20% fetal bovine serum (FBS) (Hyclone) at 37 uC in 5% CO 2 . For differentiation treatment, C2C12 cells were plated on gelatine-coated plates, allowed to reach confluence, and then switched to DMEM 2% donor equine serum (Hyclone). Human brain and glioma samples were obtained from the Bartoli Brain Tumor Bank at the Columbia University Medical Center. Samples were homogenized and used for Trizol RNA extraction and western blotting as described 30 . In all cases, immunoblots were scanned and quantified using the LI-COR Odyssey system. c-myc shRNA DNA sequences were purchased from Invitrogen and cloned into the pRS vector (Origene). shRNA constructs were transfected into NIH-3T3 cells and stable cell lines were selected with puromycin for RNA isolation and immunoblotting. The PKM1/ PKM2 ratio was analysed by extracting total RNA from cells and tissue samples and performing RT-PCR followed by PstI, Tth111I, or EcoNI digestion. qPCR for PTB, hnRNPA1 and hnRNPA2 in control and c-Myc knockdown cells was performed with SYBR green from Fermentas using the Applied Biosystems 7300 real-time PCR system. hnRNPA1 promoter sequence for dual luciferease reporter (DLR) assay was cloned into the PGL3-enhancer vector (Promega) and DLR assays were performed using the Dual Luciferase Reporter Assay System (Promega).
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. ) and resolved them by SDS-PAGE. The RNA affinity pull-down experiment and immunoprecipitation was preformed as described 7 . The 59 biotinylated EI9(50-68) and I8 RNA oligonucleotides were purchased from Dharmacon. Antibodies were bound to protein A-agarose beads before immunoprecipitation. We used the following antibodies for immunoprecipitation: BB7 for PTB, and MC3 for U2AF65. In vitro and in vivo splicing assays. A minigene containing PKM gene exon 8, exon 9, exon 10, exon 11 and flanking regions was cloned into pcDNA3 vector (Invitrogen). G to C mutation was introduced in the minigene by PCR-based sitedirected mutagenesis 11 . Wild-type and mutated minigene vectors were transfected into HeLa cells. Twenty-four hours after transfection, cells were collected and the PKM1/PKM2 ratio was analysed using RT-PCR followed by PstI digestion. In vitro splicing substrates were constructed by replacing the first exon and downstream intronic sequence of AdML pre-mRNA with PKM exon 9 and downstream intron 9 sequences or sequence with mutated hnRNPA1 binding site. Pre-mRNA substrates were synthesized by in vitro transcription using T7 RNA polymerase (Promega) following product protocol. In vitro splicing of the wild-type and mutated pre-mRNA was carried out using HeLa nuclear extract as described 31 . RNA interference. We carried out RNA interference of PTB and hnRNPA1 and hnRNPA2 as described 7 . Briefly, we plated HeLa, 293, MCF-7, or U87 cells at 2.5-3 3 10 4 cells per well in 24-well plates. The next day, we mixed 50 pmol of hnRNPA1 duplex RNA and 25 pmol of the other duplex RNAs with 1.5 ml lipofectamine 2000 transfection reagent (Invitrogen) plus 100 ml of Opt-MEM medium and added this to cells after RNA duplex-lipid complex formation. For double and triple knockdowns in HeLa and 293 cells, RNA duplexes were transfected simultaneously. The control RNA duplex was used to ensure that parallel experiments had equal amounts of RNA. In MCF-7 and U87 cells, the second and third RNA duplexes were transfected 6 h after the previous transfection. Seventytwo hours after transfection, we collected cells for RNA isolation and immunoblotting. We used the following siRNAs (Dharmacon; the sense strand sequences are given): human hnRNPA1, 59-CAGCUGAGGAAGCUCUUCA-39; human
